Cargando…

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer

BACKGROUND: MammaPrint was developed as a diagnostic tool to predict risk of breast cancer metastasis using the expression of 70 genes. To better understand the tumor biology assessed by MammaPrint, we interpreted the biological functions of the 70-genes and showed how the genes reflect the six hall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Sun, Roepman, Paul, van’t Veer, Laura J, Bernards, Rene, de Snoo, Femke, Glas, Annuska M
Formato:	Texto
Lenguaje:	English
Publicado:	Libertas Academica 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999994/ https://www.ncbi.nlm.nih.gov/pubmed/21151591 http://dx.doi.org/10.4137/BMI.S6184

Ejemplares similares

Prognostic Value of MammaPrint(®) in Invasive Lobular Breast Cancer
por: Beumer, Inès J., et al.
Publicado: (2016)

MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early‐stage breast cancer patients
por: Haan, Josien C., et al.
Publicado: (2021)

Equivalence of MammaPrint array types in clinical trials and diagnostics
por: Beumer, Inès, et al.
Publicado: (2016)

A breast cancer gene signature for indolent disease
por: Delahaye, Leonie J. M. J., et al.
Publicado: (2017)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
por: Viale, Giuseppe, et al.
Publicado: (2016)

A Prognostic Gene Expression Profile That Predicts Circulating Tumor Cell Presence in Breast Cancer Patients
por: Molloy, Timothy J., et al.
Publicado: (2012)

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014)

Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
por: Fatima, Areej, et al.
Publicado: (2017)

A gene expression profile for detection of sufficient tumour cells in breast tumour tissue: microarray diagnosis eligibility
por: Roepman, Paul, et al.
Publicado: (2009)

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction
por: Tian, Sun, et al.
Publicado: (2013)

A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
por: Dubsky, P., et al.
Publicado: (2020)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
por: Soliman, Hatem, et al.
Publicado: (2020)

Converting a breast cancer microarray signature into a high-throughput diagnostic test
por: Glas, Annuska M, et al.
Publicado: (2006)

Expression profiling predicts outcome in breast cancer
por: van 't Veer, Laura J, et al.
Publicado: (2003)

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER(+), HER2(−) early breast cancer
por: Exner, R, et al.
Publicado: (2014)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Myburgh, Ettienne J., et al.
Publicado: (2021)

Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint
por: Amezcua-Gálvez, Jesús Eduardo, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Gene Co-Expression Modules as Clinically Relevant Hallmarks of Breast Cancer Diversity
por: Wolf, Denise M., et al.
Publicado: (2014)

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Lee, Young Joo, et al.
Publicado: (2021)

RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
por: Mansani, Fabio Postiglione, et al.
Publicado: (2022)

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
por: Slembrouck, Laurence, et al.
Publicado: (2019)

EPIGENETIC PROFILES OF BIOLOGICAL AGING HALLMARKS
por: Leung, Diana L, et al.
Publicado: (2019)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer
por: Peláez-García, Alberto, et al.
Publicado: (2017)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer
por: Bösl, Andreas, et al.
Publicado: (2017)

Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
por: Wuerstlein, R., et al.
Publicado: (2019)

Genetic and biological hallmarks of colorectal cancer
por: Li, Jiexi, et al.
Publicado: (2021)

Clinically high-risk breast cancer displays markedly discordant molecular risk predictions between the MammaPrint and EndoPredict tests
por: Jahn, Stephan Wenzel, et al.
Publicado: (2020)

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
por: Hwang, Young Sol, et al.
Publicado: (2022)

Hallmarks of cancer and hallmarks of aging
por: Blagosklonny, Mikhail V.
Publicado: (2022)

The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
por: Xin, Ling, et al.
Publicado: (2017)

A Computational Workflow Translates a 58-Gene Signature to a Formalin-Fixed, Paraffin-Embedded Sample-Based Companion Diagnostic for Personalized Treatment of the BRAF-Mutation-Like Subtype of Colorectal Cancers
por: In’t Veld, Sjors G. J. G., et al.
Publicado: (2017)

PRAME expression and clinical outcome of breast cancer
por: Epping, M T, et al.
Publicado: (2008)

The microbiome and the hallmarks of cancer
por: Fulbright, Laura E., et al.
Publicado: (2017)

Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer()
por: Vaklavas, Christos, et al.
Publicado: (2020)

MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience
por: Espinel, C. Francisco, et al.
Publicado: (2012)

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction
por: Yao, Kevin, et al.
Publicado: (2022)

Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
por: Dai, Xiaofeng, et al.
Publicado: (2016)

The biological implications of Yin Yang 1 in the hallmarks of cancer
por: Meliala, Ian Timothy Sembiring, et al.
Publicado: (2020)

Platelets in the tumor microenvironment and their biological effects on cancer hallmarks
por: Chen, Lilan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d0qvc75j3iqk7uj2dtdt8o3i3n